Table 2. Anti-epileptic drug use and risk of obstructive sleep apnea syndrome (OSAS).
| OSAS characteristics | Number of antiepileptic drugs n (%) | Total | ||
|---|---|---|---|---|
| Monotherapy | Dual therapy | Poly therapy | ||
| Risk | ||||
| Low | 50 (92.6) | 28 (87.5) | 11 (91.7) | 89 (90.8) |
| High | 4 (7.4) | 4 (12.5) | 1 (8.3) | 9 (9.2) |
| Total | 54 (100) | 32 (100) | 12 (100) | 98 (100) |
| Daytime sleepiness | ||||
| Negative | 52 (96.3) | 28 (87.5) | 10 (83.3) | 90 (91.8) |
| Positive | 2 (3.7) | 4 (12.5) | 2 (16.7) | 8 (8.2) |
| Total | 54 (100) | 32 (100) | 12 (100) | 98 (100) |
| Apnea | ||||
| Nearly everyday | 0 (0) | 1 (3.1) | 0 (0) | 1 (1) |
| 3–4 times a week | 2 (3.7) | 0 (0) | 2 (16.7) | 4 (4.1) |
| 1–2 times a week | 2 (3.7) | 0 (0) | 1 (8.3) | 3 (3.1) |
| 1–2 times per month | 7 (13) | 5 (15.6) | 1 (8.3) | 13 (13.3) |
| Never | 43 (79.6) | 26 (81.3) | 8 (66.7) | 77 (78.6) |
| Total | 54 (100) | 32 (100) | 12 (100) | 98 (100) |